Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight

Summary

DelveInsight market analysis highlights hypertrophic cardiomyopathy market growth driven by increased disease awareness and targeted therapies including Lexicon Pharmaceuticals' Sotagliflozin (ZYNQUISTA) and other disease-modifying agents beyond conventional treatments.